Allogene Therapeutics develops AlloCAR T™ products, utilizing multiplex gene-engineering and proprietary lymphodepletion techniques to create allogeneic CAR T therapies for blood cancers and autoimmune diseases. Their approach addresses the limitations of autologous CAR T therapies by enabling scalable, off-the-shelf treatments that can serve over 100 patients from a single manufacturing run.
Funding
$110M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Autologous CAR T-cell therapies, while effective for certain cancers, face limitations in scalability, high costs, and complex logistics, hindering widespread patient access. The personalized nature of autologous treatments, which require using a patient's own cells, creates manufacturing bottlenecks and delays in treatment delivery.
Solution
Allogene Therapeutics develops allogeneic CAR T-cell (AlloCAR T™) therapies, an off-the-shelf approach that overcomes the limitations of autologous CAR T-cell treatments. AlloCAR T™ therapies are manufactured from healthy donor cells, enabling large-scale production and immediate availability for patients. By utilizing multiplex gene-engineering and proprietary lymphodepletion techniques, Allogene aims to deliver readily accessible, cost-effective, and consistent CAR T-cell therapies for a broad range of hematologic malignancies and autoimmune diseases. A single manufacturing run of AlloCAR T™ cells can potentially treat over 100 patients, significantly improving treatment accessibility and reducing costs.
Target Audience
The primary target audience includes patients with blood cancers and autoimmune diseases who are eligible for CAR T-cell therapy, as well as healthcare providers and institutions seeking scalable and readily available treatment options.
Features
- Utilizes multiplex gene-engineering and gene-editing capabilities to create allogeneic CAR T-cells.
- Employs a proprietary lymphodepletion platform to enhance AlloCAR T-cell engraftment and efficacy.
- Offers scalable and efficient manufacturing processes, enabling the production of therapies for a large number of patients from a single batch.
- Developing cemacabtagene ansegedleucel (cema-cel) for frontline treatment in LBCL.
- Developing ALLO-316 for clear cell renal cell carcinoma (ccRCC).
- Developing ALLO-329 for autoimmune diseases.